Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Chemoradiotherapy in Unresectable Stage III NSCLC
NCT04111913Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2019
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04111913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111913.